Atorvastatin/irbesartan - Hanmi Pharmaceuticals
Alternative Names: HCP0912; Irbesartan/atorvastatin; Irbestin; RovelitoLatest Information Update: 07 Feb 2019
At a glance
- Originator Hanmi Pharmaceutical
- Developer Hanmi Pharmaceutical; Sanofi
- Class Antihyperlipidaemics; Biphenyl compounds; Fatty acids; Heart failure therapies; Heptanoic acids; Pyrroles; Small molecules; Spiro compounds; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia; Hypertension
Most Recent Events
- 07 Feb 2019 Chemical structure information added
- 31 Dec 2013 Launched for Hyperlipidaemia in South Korea (PO)
- 31 Dec 2013 Launched for Hypertension in South Korea (PO)